NHS refuses to cover Ocrevus for primary progressive MS; OxStem taps veteran drug hunter Georg Terstappen as CSO
→ UK drug price watchdog NICE is not recommending NHS coverage of Roche’s Ocrevus for primary progressive multiple sclerosis. The decision immediately triggered an outcry from patient groups. The drug is covered for the relapsing/remitting form of the disease, but has less decisive data to back it up as a unique entry for the primary progressive form of the disease. Roche suggested a confidential price to compromise on that, but red tape is preventing the watchdogs from considering it. You can expect plenty more debate on this one.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
